tiprankstipranks
Advertisement
Advertisement
Akeso’s AK104 Kidney Cancer Trial Completion: What Investors Should Watch Next
PremiumCompany AnnouncementsAkeso’s AK104 Kidney Cancer Trial Completion: What Investors Should Watch Next
1M ago
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
Premium
Company Announcements
Akeso Shareholders Approve All Resolutions at 2026 AGM, Renewing Board Mandates and Capital Powers
1M ago
Akeso’s Ebronucimab Manufacturing Study Reaches Completion, Trimming Risk in a Crowded Cholesterol Market
Premium
Company Announcements
Akeso’s Ebronucimab Manufacturing Study Reaches Completion, Trimming Risk in a Crowded Cholesterol Market
2M ago
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
PremiumCompany AnnouncementsAkeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
2M ago
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
Premium
Ratings
Akeso: Robust FY25 Execution and Late‑Stage Oncology Pipeline Drive Upside and Higher Target Price
5M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
5M ago
Akeso Schedules Board Meeting to Approve 2025 Annual Results
PremiumCompany AnnouncementsAkeso Schedules Board Meeting to Approve 2025 Annual Results
5M ago
Akeso Advances AK112 Trial in Liver Cancer, Setting Up a New Catalyst for HK:9926
Premium
Company Announcements
Akeso Advances AK112 Trial in Liver Cancer, Setting Up a New Catalyst for HK:9926
5M ago
Akeso Completes Key Early-Stage Cancer Trial, Keeping Investor Focus on Pipeline Upside
Premium
Company Announcements
Akeso Completes Key Early-Stage Cancer Trial, Keeping Investor Focus on Pipeline Upside
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100